Key clinical point: Compared with circulating tumor DNA (ctDNA)-negative patients, ctDNA-positive patients are at a higher risk for recurrence and have a poorer prognosis for recurrence-free survival (RFS) after colorectal cancer (CRC) surgery and adjuvant chemotherapy (ACT).
Major finding: After CRC surgery and ACT, ctDNA-positive vs -negative patients were at a higher risk for CRC recurrence (relative risk [RR] 4.43 and RR 5.77, respectively; both P < .05) and had a worse prognosis for RFS (adjusted hazard ratio, 10.74 and adjusted RR 22.09, respectively; both P < .05).
Study details: This was a meta-analysis of 14 studies including 2393 patients who underwent radical R0 resection for primary CRC.
Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.
Source: Mi J et al. Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: A meta-analysis. Eur J Clin Invest. 2022 (Jul 20). Doi: 10.1111/eci.13842